The Company’s key objective is to develop and market new drugs for patients with unmet medical needs.

Neuropharm is working in collaboration with clinical investigators, scientists, manufacturers and patient networks in the United States of America and Europe to deliver advanced solutions for the treatment of CNS disorders.

Our lead products are for the treatment of autism and Fragile X syndrome.

Effective & Clinically Preferred Solutions

Neuropharm identifies and rapidly validates effective drugs for target CNS indications and aims to improve patient compliance, safety and ease of use by using the latest drug delivery technologies.

Empowering Patients & Practitioners

Neuropharm works closely with clinicians and patients, as partner of choice for the development of cost effective, tailored medications for niche or orphan CNS disorders.

Making a Real Difference to Quality of Life

Neuropharm develops products that will make substantial improvements to the quality of life for patients and their carers, whilst bringing economic benefits for healthcare providers.

Unique Products & Brands for Special Patients

Neuropharm works alongside specialist partners with expertise and intellectual property in drug delivery technology and manufacturing processes to optimise each product, recognising the importance of patent and brand protection for its products.

Available to Patients Internationally

Neuropharm works closely with regulators to ensure that its products are developed, validated and manufactured under appropriate conditions to meet international regulatory requirements.

A Glimpse into the Future

Neuropharm is collaborating with researchers to translate the rapidly advancing knowledge of neurobiology into clinical practice, gaining unique insights. These insights can help identify potential medicines that may modify the underlying basis of disease and can be rapidly developed for patients with CNS disorders.